Brain stimulation over the right inferior frontal gyrus for autism spectrum disorder
Tests theta burst brain stimulation in children and young adults with autism.
Plain-language title generated from the registry record
Registry title: Explore the Impacts of Theta Burst Stimulation Over the Right Inferior Frontal Gyrus in Autism Spectrum Disorder: Combination of Clinical Symptoms, Neuropsychological Function and MRI
Key facts
- Where
- Taoyuan, TaiwanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 30 years old?
Source: NCT07579494, who can take part
Where in Taiwan
- Chang Gung Memorial HospitalTaoyuan, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung Memorial Hospital
- Trial code
- NCT07579494
- Record updated
- 12 May 2026
- Original description
Exploring the therapeutic efficacy of Theta Burst Stimulation (TBS) over the right inferior frontal gyrus (RIFG) in autism, including changes in core symptoms, adaptive functioning, neuropsychological performance, and neurophysiological signals.Read full original descriptionShow less
Explore the Impacts of Theta Burst Stimulation Over the Right Inferior Frontal Gyrus in Autism Spectrum Disorder: Combination of Clinical Symptoms, Neuropsychological Function and MRI
Exploring the therapeutic efficacy of Theta Burst Stimulation (TBS) over the right inferior frontal gyrus (RIFG) in autism, including changes in core symptoms, adaptive functioning, neuropsychological performance, and neurophysiological signals.
Inclusion: Participants aged 8 to 30 years with a clinical diagnosis of Autism Spectrum Disorder (ASD), confirmed by the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition); DSM-5 severity level of ASD: level 1 or level 2; Participants who have been on a stable treatment regimen prior to the study, or those for whom conventional treatments have been assessed as ineffective by a physician, or those who decline conventional treatment; A score of ≥ 15 on the University of California Brief Assessment of Capacity to Consent (UBACC) and demonstrated understanding of study aims and risks via the teach-back method.
Exclusion: Previous or current severe neurological disorders, especially epilepsy, visual or auditory impairments; Previous or current severe systemic diseases such as cardiovascular disease, diabetes or hypertension; Previous or current severe brain injury; Implementation of metal materials such as a pacemaker or medication pump; Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse; Previous brain surgery or central nerve system infection; Concurrent use of medications which increased the risk of seizure attack; Concurrent use of antiepileptic drugs; Currently taking tricyclic antidepressants (TCAs), analgesics, or any medications known to lower the seizure threshold; Withdrawal Criteria:; Start to use antiepileptic drugs during study period; Changes in the frequency or dosage of concurrent treatments during the study period; Have experienced sleep disorders during brain stimulation; Current major depressive disorder; Seizure attack during the study period; Pregnancy; Presence of significant brain abnormalities, such as intracranial space-occupying lesions; Participate in another clinical trial within one month; With damaged skin at the stimulated region; With multiple sclerosis; With large ischemic scars; Severe alcoholism; Uncontrollable migraines due to increased intracranial pressure; Unsuitable for MRI (e.g. those with claustrophobia); Unsuitable for EEG; DSM-5 severity level of ASD: level 3; Suicidal ideation within one year; Autistic symptoms worsened obviously during the study period (change of DSM-5 severity level); Extreme agitation or irritability during the study period; Participants request; Clinical symptoms worsened obviously during study period; Suicidal ideation or self-harm behaviors during study period.